Raymond James & Associates Precigen, Inc. Transaction History

Raymond James & Associates

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$0.88 - $2.19 $557 - $1,386	-633 Reduced 0.36%	174,859 $185,000
Q4 2022 Feb 08, 2023	BUY	$1.27 - $2.26 $209,115 - $372,127	164,658 Added 1519.83%	175,492 $266,000
Q1 2022 May 11, 2022	SELL	$1.91 - $3.98 $2,626 - $5,472	-1,375 Reduced 11.26%	10,834 $23,000
Q4 2021 Feb 08, 2022	SELL	$3.53 - $5.5 $20,650 - $32,175	-5,850 Reduced 32.39%	12,209 $45,000
Q3 2021 Nov 02, 2021	BUY	$4.99 - $6.55 $4,241 - $5,567	850 Added 4.94%	18,059 $90,000
Q2 2021 Aug 11, 2021	BUY	$6.24 - $8.22 $4,992 - $6,576	800 Added 4.88%	17,209 $112,000
Q1 2021 May 14, 2021	BUY	$6.74 - $10.95 $5,580 - $9,066	828 Added 5.31%	16,409 $113,000
Q4 2020 Feb 12, 2021	BUY	$3.75 - $10.56 $58,428 - $164,535	15,581 New	15,581 $159,000
Q3 2020 Nov 04, 2020	SELL	$3.5 - $6.2 $72,278 - $128,036	-20,651 Closed	0 $0
Q2 2020 Jul 28, 2020	SELL	$2.16 - $5.46 $37,767 - $95,468	-17,485 Reduced 45.85%	20,651 $103,000
Q1 2020 Apr 21, 2020	BUY	$1.46 - $7.19 $55,678 - $274,197	38,136 New	38,136 $130,000

142

161M

232K

69K

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $318M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.